CD4+ T cells in cancer
Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
Identification of neoantigens for individualized therapeutic cancer vaccines
Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …
recognized by autologous T cells in the host. As neoepitopes are not subject to central …
[HTML][HTML] Lymph node colonization induces tumor-immune tolerance to promote distant metastasis
For many solid malignancies, lymph node (LN) involvement represents a harbinger of
distant metastatic disease and, therefore, an important prognostic factor. Beyond its utility as …
distant metastatic disease and, therefore, an important prognostic factor. Beyond its utility as …
[HTML][HTML] Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the
importance of addressing whether the total CD4+ and CD8+ T cell recognition is also …
importance of addressing whether the total CD4+ and CD8+ T cell recognition is also …
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature reviews Clinical oncology, 2021 - nature.com
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
BC Creelan, C Wang, JK Teer, EM Toloza, J Yao… - Nature medicine, 2021 - nature.com
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …
The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
PMK Westcott, F Muyas, H Hauck, OC Smith… - Nature Genetics, 2023 - nature.com
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
T cells are involved in control of SARS-CoV-2 infection. To establish the patterns of
immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific …
immunodominance of different SARS-CoV-2 antigens and precisely measure virus-specific …